Heron Therapeutics (HRTX) Projected to Post Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Heron Therapeutics to post earnings of ($0.02) per share and revenue of $37.08 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Trading Down 1.7 %

Shares of NASDAQ:HRTX traded down $0.04 during midday trading on Friday, hitting $2.31. The stock had a trading volume of 1,458,539 shares, compared to its average volume of 2,306,930. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93. The stock has a 50 day moving average price of $2.18 and a two-hundred day moving average price of $1.80. The company has a market capitalization of $351.88 million, a PE ratio of -12.83 and a beta of 1.39.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. StockNews.com downgraded Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.